| Registered No. |
Intervention |
Vaccine Type |
Start Year |
Patient |
Phase |
Sponsor |
Status |
| NCT00610389 |
DC loaded with autologous tumor |
Therapeutic vaccine |
2008 |
Metastatic HCC |
II |
Clinica Universidad de Navarra |
Unknown |
| NCT01128803 |
Autologous DCs loaded with AFP peptides |
Therapeutic vaccine |
2009 |
AFP ≥ 40 ng/ml |
I/II |
Nantes University Hospital |
Terminated |
| NCT00669136 |
AFP + GM-CSF plasmid prime and AFP adenoviral vector boost |
Therapeutic vaccine |
2009 |
Locoregionally treated HCC |
I/II |
Lisa H. Butterfield, Ph.D. |
Terminated due to poor accrual |
| NCT01828762 |
Autologous DCs incubated with irradiated autologous tumor stem cells and suspended in GM-CSF |
Therapeutic vaccine |
2012 |
Candidates for resection |
I |
Cellular Biomedicine Group Ltd. |
Completed |
| NCT01522820 |
DEC-205/NY-ESO-1 fusion protein CDX-1401 vaccine |
Therapeutic vaccine |
2012 |
After resection and TACE |
I |
Roswell Park Cancer Institute |
Not recruiting |
| NCT01974661 |
Allogenic DC based therapeutic vaccine |
Therapeutic vaccine |
2013 |
Not eligible for curative treatment or TACE |
I |
Immunicum AB |
Recruiting |
| NCT01923233 |
ALLOSTIM(TM) in-situ vaccine in combination with RFA |
Therapeutic vaccine |
2013 |
Refractory HCC |
I |
ImmunovativeTherapies, Ltd. |
withdrawn prior to enrollment |
| NCT02232490 |
hepcortespenlisimut-L (V5) |
Therapeutic vaccine |
2015 |
Advanced HCC |
III |
Lisichansk Regional Tuberculosis Dispensary |
Recruiting |
| |
